Compare VNET Group Inc (VNET) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs Viatris Inc — how do they compare? VNET Group Inc trades at $7.5 (market cap $2.13B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 8.8× VNET Group Inc's market cap, and Viatris Inc pays a 2.95% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| VNET | VTRS | |
|---|---|---|
Market Cap | $2.13B | $18.69B |
Sector | Technology | Health |
52-Week High | $14.03 | $17.86 |
52-Week Low | $6.29 | $9.49 |
Enterprise Value | $5.28B | $30.81B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.33, up 4.56% in the last 24 hours, but technical indicators signal a bearish trend with RSI near overbought levels. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth, with Q2 2026 earnings due August 18, 2026.
The outlook remains mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio pose risks. Investment opportunity hinges on execution of capacity expansions and AI demand, while volatility from options trading and legal settlements adds uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
